Abstract
The transient receptor potential vanilloid 1(TRPV1) channel has been a topic of great interest, since its discovery in 1997. It is a homotetrameric non-selective cation channel predominantly expressed in a population of sensory neurons and its involvement in different modalities of pain has been extensively studied. However, TRPV1 has also been shown to be expressed in non-sensory neurons and non-neuronal cells. TRPV1 is considered as a potential target for drug development, based on its tissue distribution and its role in physiological functions. Here, we summarize the evidences for disease-related alterations in TRPV1 expression and function and review the current perspectives for the therapeutic potential of TRPV1 agonists and antagonists in the treatment of a wide range of diseases.
Keywords: TRPV1, nociceptors, inflammatory mediators, pain, nociceptive ion channels, Drug Development, homotetrameric non-selective cation channel, modalities of pain, non-sensory neurons, non-neuronal cells, tissue distribution, disease-related alterations in TRPV1 expression, ion channels, by pro-inflammatory agents, thermal inflammatory pain
Current Topics in Medicinal Chemistry
Title: Disease-Related Changes in TRPV1 Expression and Its Implications for Drug Development
Volume: 11 Issue: 17
Author(s): Louis S. Premkumar and Mahendra Bishnoi
Affiliation:
Keywords: TRPV1, nociceptors, inflammatory mediators, pain, nociceptive ion channels, Drug Development, homotetrameric non-selective cation channel, modalities of pain, non-sensory neurons, non-neuronal cells, tissue distribution, disease-related alterations in TRPV1 expression, ion channels, by pro-inflammatory agents, thermal inflammatory pain
Abstract: The transient receptor potential vanilloid 1(TRPV1) channel has been a topic of great interest, since its discovery in 1997. It is a homotetrameric non-selective cation channel predominantly expressed in a population of sensory neurons and its involvement in different modalities of pain has been extensively studied. However, TRPV1 has also been shown to be expressed in non-sensory neurons and non-neuronal cells. TRPV1 is considered as a potential target for drug development, based on its tissue distribution and its role in physiological functions. Here, we summarize the evidences for disease-related alterations in TRPV1 expression and function and review the current perspectives for the therapeutic potential of TRPV1 agonists and antagonists in the treatment of a wide range of diseases.
Export Options
About this article
Cite this article as:
S. Premkumar Louis and Bishnoi Mahendra, Disease-Related Changes in TRPV1 Expression and Its Implications for Drug Development, Current Topics in Medicinal Chemistry 2011; 11 (17) . https://dx.doi.org/10.2174/156802611796904834
DOI https://dx.doi.org/10.2174/156802611796904834 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transposable Elements in Cancer and Other Human Diseases
Current Cancer Drug Targets Focal Adhesion Kinase: From In Vitro Studies to Functional Analyses In Vivo
Current Protein & Peptide Science Fragmented ECG as a Risk Marker in Cardiovascular Diseases
Current Cardiology Reviews Glucagon-Like Peptide 1 and the Cardiovascular System
Current Diabetes Reviews A Review on Natural Sources Derived Protein Nanoparticles as Anticancer Agents
Current Topics in Medicinal Chemistry Genetic Variations of the Hemostatic System as Risk Factors for Venous and Arterial Thrombotic Disease
Current Genomics Cardiovascular Effects of Neuregulin-1/ErbB Signaling: Role in Vascular Signaling and Angiogenesis
Current Pharmaceutical Design Mechanisms for Progenitor Cell-Mediated Repair for Ischemic Heart Injury
Current Stem Cell Research & Therapy Turnover Studies on Cardiac Natriuretic Peptides: Methodological,Pathophysiological and Therapeutical Considerations.
Current Drug Metabolism Hsp70 Protein Complexes as Drug Targets
Current Pharmaceutical Design QT Alterations in Psychopharmacology: Proven Candidates and Suspects
Current Drug Safety Basal Septal Hypertrophy
Current Cardiology Reviews Rational Autologous Cell Sources For Therapy of Heart Failure - Vehicles and Targets For Gene and RNA Therapies
Current Gene Therapy Functions of Fukutin, a Gene Responsible for Fukuyama Type Congenital Muscular Dystrophy, in Neuromuscular System and Other Somatic Organs
Central Nervous System Agents in Medicinal Chemistry Prevalence of Cardiovascular and Metabolic Events in Patients Prescribed Clozapine: A Retrospective Observational, Clinical Cohort Study
Current Drug Safety Matrix Metalloproteinases as Valid Clinical Target
Current Pharmaceutical Design The Multi-modality Cardiac Imaging Approach to Cardiac Sarcoidosis
Current Medical Imaging Susceptibility Risk Alleles of -238G/A, -308G/A and -1031T/C Promoter Polymorphisms of TNF-α Gene to Uterine Leiomyomas
Recent Advances in DNA & Gene Sequences (Discontinued) Autophagy: A Major Target of Cadmium Nephrotoxicity
Current Chemical Biology CA125: An Increasingly Promising Biomarker of Heart Failure
Current Pharmaceutical Design